SANDRA META SWAIN, M.D.
Osteopathic Medicine in Bethesda, MD
License number
Maryland D-29517
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
8901 Wisconsin Ave Bldg 8 ROOM 5101, Bethesda, MD 20889
Phone
(301) 435-5416
(301) 496-0047 (Fax)
(301) 365-9206
(301) 496-0047 (Fax)
(301) 365-9206
Personal information
See more information about SANDRA META SWAIN at radaris.comName
Address
Phone
3714 E Northern Pkwy #1, Baltimore, MD 21206
9520 Eagle Ridge Dr, Bethesda, MD 20817
2511 Burridge Rd, Parkville, MD 21234
9520 Eagle Ridge Dr, Bethesda, MD 20817
Professional information
Method Of Selecting Cancer Patients For Anti-Angiogenesis Therapy In Combination With Chemotherapy
US Patent:
2014006, Mar 6, 2014
Filed:
Mar 1, 2012
Appl. No.:
14/002455
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Seth M. Steinberg - North Potomac MD, US
Sandra M. Swain - Bethesda MD, US
Seth M. Steinberg - North Potomac MD, US
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVIC - Bethesda MD
International Classification:
G01N 33/574
US Classification:
514 34, 514 49, 514449, 435 792
Abstract:
What is described is a method for identifying a cancer patient that is amenable to anti-angiogenesis therapy in combination with chemotherapy for longer overall survival and/or progression-free survival by measuring the status of tumor cell HER2 expression, p53 expression, and apoptosis or endothelial cell CD31 expression in a tumor sample obtained from the patient prior to treatment. Bevacizumab, an antibody to vascular endothelial growth factor, is a preferred anti-angiogenesis therapy for treating several cancer types including breast cancer. Cancer patients with p53-negative or HER2 negative tumors, especially dual p53 HER2-negative tumors or tumors with low levels of apoptosis or high endothelial cell CD31 expression in the tumor samples are more amenable to anti-angiogenesis therapy with bevacizumab. These tumor characteristics provide a diagnostic method for identifying cancer patients amendable to anti-angiogenesis therapy plus chemotherapy for better treatment outcome.
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
US Patent:
2012014, Jun 7, 2012
Filed:
May 21, 2010
Appl. No.:
13/322140
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Sandra M. Swain - Bethesda MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD
International Classification:
A61K 31/337, G01N 21/75, C40B 30/04, A61K 31/704, A61P 35/04, G01N 33/566, A61P 35/00
US Classification:
514 34, 435 71, 514449, 506 9
Abstract:
Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.
Akt Phosphorylation At Ser473 As An Indicator For Taxane-Based Chemotherapy
US Patent:
2014001, Jan 9, 2014
Filed:
Sep 19, 2013
Appl. No.:
14/031699
Inventors:
Sherry X. Yang - Ellicott City MD, US
Sandra M. Swain - Bethesda MD, US
Sandra M. Swain - Bethesda MD, US
International Classification:
G01N 33/574
US Classification:
514449, 435 74
Abstract:
Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer.